Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection

    NEXT STORY
    Jackson Memorial Hospital gives Philips Enterprise Monitoring as a Service model high marks for satisfaction and efficiency
    PREV STORY
    I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Rockwell Medical, Inc. to Sponsor Triferic® Exhibitor Spotlight Presentation at American Society of Nephrology Conference

    author_avatar
    NASDAQ Market News

    Generex Signs Letter of Intent with Kiromic to Merge with NuGenerex Immuno-Oncology Forming a Multi-Platform Clinical Stage Immunotherapy Company

    author_avatar
    NASDAQ Market News

    AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients

    author_avatar
    NASDAQ Market News